Back to News
Market Impact: 0.15
RPRX Crosses Above Average Analyst Target
Source: Nasdaq
Analyst InsightsMarket Technicals & Flows
Royalty Pharma shares recently traded at $67.18, above the average analyst 12-month target price of $66.00. The article notes analysts may reassess their targets or ratings when a stock reaches its target, but the provided text reports no specific analyst action.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
RPRX0.10
More News
- Oil price falls amid hope of a breakthrough to end Iran war
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Binance seeks to shore up confidence after record $6.3 billion heist
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?